Verastem, Inc. (VSTM), Wednesday announced preliminary clinical data from RAMP 203 Phase 1/2 study, evaluating the combination of avutometinib and sotorasib plus defactinib in patients with KRAS G12C mutant advanced non-small cell lung cancer.
The company administered 960 mg of sotorasib on a daily basis, and avutometinib 3.2 mg twice-weekly plus defactinib 200 mg twice-daily in three patients whose cancer previously progressed on a G12C inhibitor.
The preliminary data showed that tumor shrank by atleast 20 percent in two patients during the initial scans. The combined therapy also demonstrated no dose-limiting toxicities in the participants.
During the pre-market hours, Verastem's stock is trading at $4.72, up 2.61 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Health News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.